Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial

AIMS/HYPOTHESIS: In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 diabetes. METHODS: Changes from baseline alanine a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sattar, Naveed, Fitchett, David, Hantel, Stefan, George, Jyothis T., Zinman, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133166/
https://www.ncbi.nlm.nih.gov/pubmed/30066148
http://dx.doi.org/10.1007/s00125-018-4702-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133166/
https://www.ncbi.nlm.nih.gov/pubmed/30066148
http://dx.doi.org/10.1007/s00125-018-4702-3

Ejemplares similares